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Fabry disease is an X-linked lysosomal storage disease caused by
deficiency of -galactosidase A that affects males and shows
disease expression in heterozygotes. The characteristic progressive
renal insufficiency, cardiac involvement, and neuropathology usu-
ally are ascribed to globotriaosylceramide accumulation in the
endothelium. However, no direct correlation exists between lipid
storage and clinical manifestations, and treatment of patients with
recombinant enzymes does not reverse several key signs despite
clearance of lipid from the endothelium. We therefore investigated
the possibility that globotriaosylceramide metabolites are a miss-
ing link in the pathogenesis. We report that deacylated globotri-
aosylceramide, globotriaosylsphingosine, and a minor additional
metabolite are dramatically increased in plasma of classically affected
male Fabry patients and plasma and tissues of Fabry mice. Plasma
globotriaosylceramide levels are reduced by therapy. We show
that globotriaosylsphingosine is an inhibitor of -galactosidase A
activity. Furthermore, exposure of smooth muscle cells, but not
fibroblasts, to globotriaosylsphingosine at concentrations ob-
served in plasma of patients promotes proliferation. The increased
intima-media thickness in Fabry patients therefore may be related
to the presence of this metabolite. Our findings suggest that
measurement of circulating globotriaosylsphingosine will be use-
ful to monitor Fabry disease and may contribute to a better
understanding of the disorder.
-galactosidase A  globotriaosylceramide  smooth muscle cell 
lysoglycolipids
Fabry disease is an X-linked lysosomal storage disorder resultingfrom deficient activity of -galactosidase A (1, 2). Lysosomal
accumulation of its substrate globotriaosylceramide (Gb3) that is
prominent in endothelial cells is thought to cause the progressive
renal insufficiency, cardiac involvement, and CNS pathology in
Fabry patients (3). Two different recombinant -galactosidase A
preparations are in use for the treatment of Fabry disease (4–6).
Although the enzyme therapies were found to result in the desired
clearance of Gb3 from the endothelium, several of the clinical
effects are not as robust as predicted. In some patients, stabilization
of renal function and improvement in cardiac hypertrophy occurs
upon therapy, but many experience progressive complications (7).
These findings suggest thatGb3 elevation and clinicalmanifestation
of Fabry disease do not necessarily correlate. Other observations
corroborate this view. A large proportion of female carriers of
Fabry disease develop symptoms similar to hemizygotes despite
considerable amounts of circulating residual enzyme (8–12). This
finding sharply contrasts with the general lack of symptoms among
heterozygote carriers of another X-linked lysosomal hydrolase
deficiency, Hunter disease. Furthermore, prominent Gb3 accumu-
lation occurs in hemizygotes at or even before birth, long before any
clinical symptoms develop (13). The discrepancy between early
storage of Gb3 and clinical symptoms also is noted in Fabry mice
generated by disruption of the -galactosidase A gene (14). The
absence of infantile manifestations in Fabry patients completely
lacking -galactosidase A activity indicates that Gb3 accumulation
does not cause immediate, and perhaps does not even directly
cause, signs of disease. Consistent with this notion, plasma or
urinary levels of Gb3 in neither hemizygotes nor heterozygotes
correlate with the severity of disease manifestations (12, 15, 16).
Plasma Gb3 concentrations in some presymptomatic boys may
exceed those in symptomatic adult hemizygotes. A recent study has
provided evidence for the presence of an unidentified substance in
plasma of symptomatic Fabry disease patients that stimulates
proliferation of vascular smoothmuscle cells and cardiomyocytes in
vitro (17). It is conceivable that this substance is a causative factor
in the development of left ventricular hypertrophy and increased
intima-media thickness in Fabry patients. Although Gb3 accumu-
lation is clearly a prerequisite for manifestation of Fabry disease,
these observations point to the existence of another factor in
addition to Gb3 that is involved in the pathogenesis of the disorder.
Here, we report that plasma of Fabry patients contains markedly
increased concentrations of deacylated Gb3, globotriaosylsphin-
gosine (lyso-Gb3). The relative increase in the plasma concentra-
tions of this cationic amphiphilic glycolipid exceeds that of Gb3 by
more than an order of magnitude. At concentrations occurring in
plasma of symptomatic Fabry patients, lyso-Gb3 promotes Gb3
storage and induces proliferation of smooth muscle cells in vitro
suggestive of a causative role of lyso-Gb3 in the pathogenesis of
Fabry disease.
Results
Identification of lyso-Gb3 in Fabry Plasma. The consideration that a
pathogenic, potentially vasoactive metabolite might be present in
plasma fromFabry patients prompted us to investigate the presence
of lyso-Gb3 (deacylated Gb3). Hitherto the existence of lyso-Gb3
has not been documented.However, various deacylated glycosphin-
golipids have been identified in lysosomal glycolipid storage dis-
eases (see discussion in ref. 18 for an overview). For example, in
Gaucher disease, glucosylsphingosine, the deacylated form of the
accumulating glucosylceramide, is known to be increased as well
(18, 19). The same holds for Krabbe disease in which galactosyl-
sphingosine or psychosine (deacylated galactosylceramide) is ele-
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vated (20–23). It has been proposed that such lysosphingolipids play
a role in the pathogenesis of these disorders (18–24). lyso-Gb3 is a
cationic amphiphile with a large polar sugar moiety, rendering it
relatively hydrophilic and water-soluble (see Fig. 1 Inset). Its
presence thereforemay have escaped attention during lipid analyses
focusing on constituents of the organic phase of extractions. By
using normal plasma spiked with a standard of pure lyso-Gb3, an
appropriate extraction procedure for lyso-Gb3 was developed.
lyso-Gb3 was recovered quantitatively from the upper phase of the
extraction according to the Bligh and Dyer procedure (25), and it
was purified by repeated extraction of the upper phase with
1-butanol (see Materials and Methods). The free amine moiety of
lyso-Gb3 was fluorescently labeled with ortho-phthaldialdehyde
according to a procedure used earlier for labeling of other ly-
sosphingolipids (26). Labeled lysosphingolipids were separated by
high-performance liquid chromatography and quantitatively ana-
lyzed (seeMaterials and Methods). Plasma samples from symptom-
atic Fabry patients were found to contain large quantities of a
compound with a retention time identical to that of authentic
lyso-Gb3 in the spiked plasma samples (Fig. 1). This compound
could not be detected in plasma from control individuals. The
identity of the abnormal structure as lyso-Gb3 was further verified.
Incubation of the plasma sample with recombinant -galactosidase
A resulted in a shift to a value coinciding with that shown by
lactosylsphingosine. Tandemmass spectrometry analysis confirmed
the identity of the abnormal structure as lyso-Gb3 [see supporting
information (SI) Text]. Examination of chromatograms of plasma
from symptomatic patients pointed to the presence of another,
more polar, abnormal compound X with a retention time of 16.2
min (see Fig. 1, Fabry plasma). Its concentration is 5-fold lower
than that of lyso-Gb3. The shift in its peak retention by 1 min after
incubation with-galactosidaseA indicates that the compound also
contains a terminal -galactoside moiety, which suggests that this
compound is presumably also a lysoglycolipid and genuine storage
product in Fabry disease. Based on its chromatographic behavior,
it seems unlikely that the compound is sphingosinedigalactoside,
the deacylated form of ceramidedigalactoside. The latter lipid has
been found to be increased in kidney of patients with Fabry disease
(27). The low abundance of the compound did not yet allow
identification of its structure by tandem mass spectrometry. The
ratio of lyso-Gb3 to the other abnormal structure in Fabry plasma
specimens was remarkably constant in one individual but varied
slightly among different patients.
Elevated lyso-Gb3 Levels in Plasma of Members of a Large Fabry
Pedigree. Plasma levels of lyso-Gb3, Gb3, lactosylceramide, glu-
cosylceramide, and ceramide were determined in members of a
large Fabry pedigree (seeMaterials and Methods). The status of all
individuals was confirmed by enzyme analysis and genotyping
(mutation encoding amino acid substitutionD136Y). Table 1 shows
that plasma specimens of the unaffected males (father and two
normal sons) showed lyso-Gb3 levels below the detection level of 10
nM and normal levels of Gb3 (1.3–1.8 M). In sharp contrast,
plasma from all five affected sons showed markedly elevated
lyso-Gb3 (195–407 nM) and elevated Gb3 (4.9–10.0 M) levels. In
female members of the family, no clear increases in plasma Gb3
were noted, independent of the genetic status of individuals.
However, lyso-Gb3 was clearly increased in the symptomatic aunt,
mother, and daughter (22–76 nM), and it was below the detection
limit in the asymptomatic daughter and the unaffected siblings.
Plasma lyso-Gb3 and Manifestations of Disease. Plotting the plasma
concentration of lyso-Gb3 against that of Gb3 for individual
members of a Dutch Fabry cohort (see SI Fig. 4) indicated that the
elevation of plasma lyso-Gb3, like that of Gb3, is most prominent
Fig. 1. Detection of lyso-Gb3 in plasma of Fabry patient. (Top) Structure of
lyso-Gb3. (Middle and Bottom) Chromatograms obtained for pure lyso-Gb3
(Middle Left), normal plasma (Bottom Left), normal plasma spiked with lyso-
Gb3 (Middle Right), and Fabry hemizygote plasma (Bottom Right).
Table 1. Plasma lyso-Gb3 and neutral glycosphingolipids in members of Fabry pedigree
Status
Age at
sampling, years MSSI lysoGb3, nM Gb3, M LacCer, M GlcCer, M Cer, M
Normal, daughter 4 0 ND 1.6 4.2 4.3 10.3
Normal, daughter 8 0 ND 1.8 4.8 5.1 7.5
Normal, daughter 17 0 ND 1.1 3.3 3.9 7.9
Heterozygous, daughter 6 0 ND 1.1 3.2 2.9 8.1
Heterozygous, daughter 14 10 22 1.6 3.6 4.1 6.2
Heterozygous, mother 41 22 36 1.7 4.9 5.0 6.9
Heterozygous, aunt 45 32 76 2.5 5.6 5.1 11.7
Normal, son 9 0 ND 1.3 4.0 4.9 7.7
Normal, son 24 0 ND NA NA NA NA
Normal, father 50 0 ND 1.8 3.7 5.4 10.7
Hemizygous, son 11 10 407 10.0 6.1 8.1 8.8
Hemizygous, son 16 20 320 6.7 3.8 4.1 6.0
Hemizygous, son 17 12 217 7.0 6.0 7.3 5.8
Hemizygous, son 18 19 222 6.0 6.5 6.2 8.6
Hemizygous, son 20 12 196 6.9 6.5 6.5 10.0
NA, not assessed; ND, 10 nM; LacCer, lactosylceramide; GlyCer, glucosylceramide plus galactosylceramide; Cer, ceramide.
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in hemizygotes. There is a strong correlation between the concen-
tration of plasma lyso-Gb3 andGb3 in hemizygous patients (n 22,
  0.75, P  0.001). In sharp contrast to the patients with classic
Fabry disease manifestations, individuals carrying the mutation
encoding R112H -galactosidase A, which is known to be associ-
ated with an atypical manifestation of symptoms (28), showed
normal Gb3 levels and very low lyso-Gb3 levels.
The relationship of individual plasma lyso-Gb3 concentrations
with age and the commonly used Mainz Severity Score Index
(MSSI) of disease severity (29) was determined (see also SI Fig. 5).
In the case of hemizygotes, no correlation was noted between
plasma lyso-Gb3 with regard to age or MSSI. Very high lyso-Gb3
concentrations were detected in plasma specimens of all classically
affected Fabry hemizygotes. Of note is that specifically young boys
with little disease manifestations already showed high plasma
lyso-Gb3. Also in the case of a newborn hemizygote, a prominently
increased lyso-Gb3 (81 nM) was demonstrable. No significant
correlation of plasma lyso-Gb3 in hemizygotes with left ventricular
mass or other disease signs was observed.
A clear exception among the hemizygotes were individuals
carrying the R112H mutation. Two atypically affected adult male
patients with the R112Hmutation (one with polyneuropathy as the
only symptom and the other with isolated renal disease, possibly
also related to hypertension) showed relatively low lyso-Gb3 con-
centrations. Their MSSI scores were 22 and 38, respectively. Three
very mildly affected, middle-aged hemizygotes for the R112H
mutation (MSSI of 2, 2, and 4) also showed very low plasma
lyso-Gb3 levels.
Examination of female heterozygotes revealed that, with increas-
ing age, lyso-Gb3 tends to be higher, although not significantly (P
0.08). In females, lyso-Gb3 also tends to be more elevated with
increasing MSSI score (Spearman’s   0.49, P  0.05). A clear
exception in this respect was a 13-year-old heterozygote showing
relatively high plasma lyso-Gb3 in combination with a lowMSSI of
6. The patient, now receiving enzyme-replacement therapy (ERT),
suffered from acroparesthesias on exercise and showed a white
matter lesion on the MRI of the brain. The latter is relatively rare
in young hemizygotes and suggests a rapidly progressive disease
manifestation. Analysis of neuropathology and renal and cardiac
involvement revealed that only left ventricular mass in Fabry
heterozygotes correlated with plasma lyso-Gb3 concentration
(Spearman’s   0.68, P  0.05). In conclusion, in Fabry hemizy-
gotes marked increases in lyso-Gb3 are noted already at young age,
with the exception of atypical carriers of the R112H mutation. In
the case of female heterozygotes, a larger series of patients has to
be analyzed to establish the relation of plasma lyso-Gb3 with age
and disease manifestations.
lyso-Gb3 in Fabry Mice. The plasma concentrations of lyso-Gb3 and
Gb3 were determined in mice. Table 2 shows that, at 20 weeks of
age, plasma lyso-Gb3 concentrations are clearly less elevated in
female heterozygousmice comparedwith femalemice homozygous
for the -galactosidase A gene disruption and male hemizygous
mice. Plasma lyso-Gb3 was found to be prominently increased at
very young age in hemizygous mice, being 476, 510, and 614 nM at
70, 138, and 243 days, respectively.
The presence of lyso-Gb3 in tissues was studied in 20-week-old
hemizygous mice. In parallel, concentrations of Gb3 and some
other glycosphingolipids were determined. Dramatic increases in
Gb3 and lyso-Gb3 concentrations were noted in most tissues of
hemizygous mice (Table 3). Very high concentrations of lyso-Gb3
were observed in liver and intestine, clearly exceeding that in
plasma. This finding suggests that lyso-Gb3 is either actively formed
or preferentially trapped in these organs.
Hydrophilic Nature of lyso-Gb3. The structure of lyso-Gb3 predicts a
high degree of solubility in water. Consistent with this notion,
lyso-Gb3 is largely recovered in the methanol/water phase upon
Bligh and Dyer extraction (see alsoMaterials and Methods). Given
the high concentration of lyso-Gb3 in plasma of symptomatic Fabry
patients, we investigated its distribution among lipoproteins. In
contrast to Gb3, which is completely lipoprotein-bound, only a very
small percentage of lyso-Gb3 was found to be associated with
lipoproteins. The vast majority of lyso-Gb3 (95%), was recovered
in the lipoprotein-free fraction, presumably associated to albumin,
as is the case with other hydrophilic lipids such as fatty acids.
Table 2. Plasma lyso-Gb3 and neutral glycosphingolipids in Fabry mice
Sex Status X, nmol/ml lysoGb3, nmol/ml Gb3, nmol/ml LacCer, nmol/ml GlyCer, nmol/ml Cer, nmol/ml
Female Heterozygote 0.004 0.035 0.2 0.1 6.4 3.0
Female Homozygote 0.143 0.737 1.9 0.1 7.1 2.2
Female Wild-type 0.010 0.010 0.1 0.2 3.2 4.5
Male Hemizygote 0.107 0.510 2.6 0.2 4.9 3.4
Male Wild-type 0.010 0.010 0.1 0.1 3.9 3.2
Mice were killed at day 138. Plasma and tissues were immediately collected, and lipids were determined as described in Materials and Methods. LacCer,
lactosylceramide; GlyCer, glucosylceramide plus galactosylceramide; Cer, ceramide.
Table 3. Tissue content on lyso-Gb3 in hemizygous Fabry mice
Status Tissue X, nmol/g lysoGb3, nmol/g Gb3, nmol/g LacCer, nmol/g GlyCer, nmol/g Cer, nmol/g
Hemizygote Aorta 0.22 0.80 234 20.1 123 84.6
Duodenum 1.33 4.10 1,083 52.3 140 264
Brain 0.15 0.53 35.7 21.3 11,400 542
Heart 0.18 0.44 242 32.0 28.6 113
Kidney 0.12 0.51 707 38.4 75.3 267
Liver 2.30 10.9 713 28.9 47.5 292
Control Aorta 0.010 0.010 4.4 5.0 137 63.8
Duodenum 0.010 0.010 5.1 14.1 111 221
Brain 0.010 0.010 4.6 23.5 10,700 628
Heart 0.010 0.010 5.2 19.5 23.3 116
Kidney 0.010 0.010 196 15.2 72.6 202
Liver 0.010 0.010 2.9 12.6 51.6 252
Mice were killed at day 138. Plasma and tissues were immediately collected, and lipids were determined as described in Materials and Methods. LacCer,
lactosylceramide; GlyCer, glucosylceramide plus galactosylceramide; Cer, ceramide.
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Unfortunately, the possibility that lyso-Gb3 is secreted into urine
can presently not be confirmed nor excluded with certainty. The
detection of lyso-Gb3 in urine samples with the present procedure
is hampered by the presence of interfering substances in this fluid.
Inhibitory Properties of lyso-Gb3 in Vitro and in Vivo. Given the
structural similarity of lyso-Gb3 to Gb3, its capacity to inhibit
-galactosidase A was investigated. First, the effect of lyso-Gb3 on
activity of recombinant -galactosidase A toward 4-methylumbe-
liferyl--galactoside was determined. Potent competitive inhibition
(Ki  34 M) was observed to be identical for the two tested
recombinant -galactosidase A preparations. The activity of re-
combinant -galactosidase A preparations towardGb3 as substrate
also was pronouncedly inhibited by the presence of lyso-Gb3. IC50
values of 20 M were observed.
Cultured fibroblasts from normal subjects accumulate Gb3 when
exposed to lyso-Gb3. An illustrative example of this is depicted in
SI Fig. 6. lyso-Gb3 at concentrations 100 nM, similar to those
encountered in plasma of symptomatic Fabry patients, is sufficient
to increase cellular Gb3. Incubation with 500 nM lyso-Gb3 resulted
in an increase of cellular Gb3 from 2.03 nmol/mg protein to 3.16
nmol/mg protein within 9 days. This effect is presumed to be caused
by inhibition of -galactosidaseA activity, but it cannot be excluded
that, after uptake, some lyso-Gb3 is converted to Gb3. An 200-
fold more potent inhibitory capacity of lyso-Gb3 in vivo compared
with in vitro could be explained by trapping of the membrane-
permeable lyso-Gb3 in the acidic lysosome. Its pKa predicts accu-
mulation of lyso-Gb3 in lysosomes by a factor of 200, coinciding
with the noted difference in apparent IC50 between in vitro and in
vivo experiments.
Biological Effect of lyso-Gb3. A characteristic feature of Fabry
disease is vascular remodeling. This phenomenon is reflected in
increased carotid intima-media thickness as the result of prolifer-
ation of smoothmuscle cells (29, 30). To establish whether lyso-Gb3
exerts itself deleterious effects on the vasculature, the influence of
the compound on smoothmuscle cell proliferation was studied. Fig.
2 shows that low (50–100 nM) concentrations of lyso-Gb3, similar
to those observed in plasma of symptomatic Fabry patients, mark-
edly promote proliferation of smooth muscle cells in culture. In
sharp contrast, the structurally related compounds like Gb3 and
lactosylsphingosine have no stimulating effect on smooth muscle
proliferation.
We did not observe any stimulation by lyso-Gb3 of proliferation
of fibroblasts (data not shown). These findings suggests that the
elevation of lyso-Gb3 in plasma of Fabry patients may underlie the
observed increase in intima-media thickness.
Degradation of lyso-Gb3 by -Galactosidase A and Effect of ERT.
lyso-Gb3 can act as substrate for -galactosidase A, resulting in its
conversion to lactosylsphingosine. Compared with Gb3, the deg-
radation of pure lyso-Gb3 in the test tube by recombinant -
galactosidase A preparations was found to be at least 50-fold less
efficient (data not shown). At neutral pH, recombinant -galacto-
sidases A hardly hydrolyze lyso-Gb3 because of their acid pH
optimum (see SI Text).
The effect of prolongedERTon plasma lyso-Gb3was studied for
a selected subset of patients. Fig. 3 shows representative examples
of the observed responses in plasma lyso-Gb3 to ERT with com-
mercially available enzyme preparations agalsidase alfa (Shire) and
agalsidase beta (Genzyme). Patients receiving either agalsidase alfa
(Fig. 3 Left) or agalsidase beta (Fig. 3 Right), without developing
antibodies, showed a reduction of lyso-Gb3 within 1 year, although
a complete normalization was not observed. Some of the male
hemizygotes lacking -galactosidase A develop neutralizing anti-
bodies upon ERT (31–33). Fig. 3B show the responses in plasma
lyso-Gb3 and Gb3 to ERT for patients that had developed anti-
bodies after receiving agalsidase alfa (Left) and agalsidase beta
(Right). Reduction of plasma lyso-Gb3 in these individuals was
relatively poor. At present, no statements can be made about the
relative efficacy of the two commercial recombinant -galactosi-
dase A preparations or the influence of enzyme dose and antibody
formation. A detailed investigation with carefully matched patients
will be required to answer these important questions.
Discussion
The striking abnormality in lyso-Gb3 in plasma of Fabry patients
noticed in this study has been overlooked for many decades, likely
because the compound is very water-soluble and does not distribute
into the organic phase during organic solvent extractions. Our
discovery of markedly elevated concentrations lyso-Gb3 in plasma
of symptomatic Fabry patients and the potential of the compound
to inhibit -galactosidase A activity and to induce smooth muscle
cell proliferation is of considerable interest. Vascular involvement
in Fabry patients is known to include an accelerated hypertrophy of
the walls of the radial artery and a thickening of the intima media
of the common carotid artery because of proliferation of smooth
muscle cells (29, 30). In the near future, a large number of patients,
in particular heterozygotes, should be studied to determine the
Fig. 2. Increased proliferation of smooth muscle cells by exposure to lyso-
Gb3. The proliferation rate of smooth muscle cells was determined as de-
scribed in Materials and Methods. Cells were exposed for 24 h to indicated
concentrations of lyso-Gb3 (), lactosylsphingosine (), or Gb3 (‚). The
incorporation of radioactive thymidine per well is depicted.
Fig. 3. Effect of ERT on plasma lyso-Gb3. Illustrative examples of responses
in plasma lyso-Gb3 in Fabry patients receiving ERT. (A) Responses in plasma
lyso-Gb3 to agalsidase alfa treatment (0.2 mg/kg body weight, 2 weeks) (Left)
or agalsidase beta treatment (0.2 mg/kg body weight, 2 weeks) (Right) in
patients developing no antibodies. All patients were hemizygotes, except two
indicated by the dotted line. (B) Response in plasma lyso-Gb3 (Œ) and Gb3 ({)
to agalsidase alfa treatment (0.2 mg/kg body weight, 2 weeks) (Left) or
agalsidase beta treatment (0.2 mg/kg body weight, 2 weeks) (Right) in pa-
tients developing antibodies. The dose of agalsidase beta was adjusted to (1.0
mg/kg body weight, 2 weeks) at 36 months of treatment.
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relationship between intima-media thickness and plasma lyso-
Gb3 levels. Left ventricular hypertrophy also is common in Fabry
disease. Of note, a correlation was observed between left
ventricular hypertrophy and plasma lyso-Gb3 concentration in
heterozygotes.
The elevated lyso-Gb3 in plasma of symptomatic patients might
partially explain the finding by Barbey et al. (17) of an unidentified
substance in plasma of symptomatic Fabry disease patients that
stimulates proliferation of vascular smooth muscle cells and cardi-
omyocytes in vitro. Elevated plasma lyso-Gb3 also may provide
plausible explanations for other poorly understood phenomena in
Fabry disease. First, the inhibitory properties of lyso-Gb3 may help
to explain the repeated finding of Gb3 accumulation in renal
transplants; prior observations already pointed to a circulating
inhibitor of -galactosidase A in Fabry patients (34, 35). Second,
manifestation of the disease in female heterozygotes, despite con-
siderable residual circulating -galactosidase A and a significant
proportion of enzyme-competent cells, becomes more understand-
able. It can be envisioned that formation of lyso-Gb3 in enzyme-
deficient cells, followed by its release into the circulation and
subsequent uptake in other cells, ultimately also will inhibit -
galactosidase A activity in enzyme-competent cells. Moreover, the
circulating lyso-Gb3 may stimulate vascular remodeling. The dis-
ease thus may eventually manifest itself in female heterozygotes as
devastatingly as inmale hemizygotes. An additional consequence of
high lyso-Gb3 concentrations in plasma also should be considered.
It is conceivable that the lyso-Gb3 after its uptake by cells subse-
quently may be acylated to Gb3, which could lead to increased
concentrations of extralysosomal Gb3. This pool of Gb3 would not
be accessible to endogenous -galactosidase A or enzyme admin-
istered during ERT. Extralysosomal accumulation of Gb3 recently
has been documented in tissues from Fabry patients (36).
The clear increase in plasma lyso-Gb3 in young hemizygotes, and
similar findings in hemizygous mice, is of particular interest. Mark-
edly elevated plasma lyso-Gb3 in a newborn is a particularly striking
finding on the basis of which it seems that, in some hemizygotes,
vascular remodeling might already be initiated at or even before
birth. This finding would imply that there exists a considerable
window between increase of plasma lyso-Gb3 and detectable
disease manifestations. In female heterozygotes, the build-up of
lyso-Gb3 clearly proceeds more slowly than in the hemizygotes.
Monitoring plasma lyso-Gb3 in clinical studies aimed on prevention
of signs and symptoms seems of interest. It is of interest to note that
Fabry mice, despite relatively high lyso-Gb3 and Gb3 contents of
plasma and kidney, do not show overt kidney disease, which
suggests that microvascular complications in the kidney are not
swiftly induced by the lipid abnormalities.
The origin of lyso-Gb3 is elusive. It might be synthesized by
sequential glycosylation of sphingoid bases and accumulate because
of the deficiency in -galactosidase A. Based on the analysis of the
sphingoid base composition, Kobayashi et al. (37) earlier suggested
that in brain from patients with GM1 gangliosidosis and GM2
gangliosidosis elevated levels of corresponding lysosphingolipids
might originate from biosynthesis and not from deacylation of
sphingolipids. Biosynthesis of galactosylsphingosine (psychosine)
from sphingosine also has been reported (20, 38). Alternatively, it
might still be that lyso-Gb3 is formed by deacylation of the stored
Gb3 in Fabry patients. The strikingly constant ratio between
lyso-Gb3 and Gb3 in individual Fabry patients and Fabry mice is
consistent with this but does not discriminate between the two
possibilities. It has to be established whether lyso-Gb3 can originate
spontaneously from stored Gb3 or even is actively formed by the
action of a specific enzyme. Candidates in this connection are the
lysosomal ceramidase, which might be promiscuous toward Gb3, or
a hitherto unknown specific glycosphingolipid deacylase. Intrain-
dividual differences in these tentative lyso-Gb3-generating enzyme
activities might conceivably impact on the age of onset and pro-
gression of Fabry disease.
Our observation that lyso-Gb3 induces smooth muscle cell
proliferation warrants additional investigations on the cellular
mechanisms involved. It already has been demonstrated that ly-
sosphingolipids can affect cellular proliferation via interference in
signal transduction. For example, sphingosine-1-phosphate is
known to stimulate proliferation of smoothmuscle cells by a variety
of signal transduction pathways includingERKandMAPK(39, 40).
Our findings suggest that Fabry disease might no longer be
viewed as a prototypic lysosomal storage disorder. Although lyso-
somal storage of Gb3 is clearly a prerequisite for manifestations of
Fabry disease, the formation of pathogenic lyso-Gb3 may be
instrumental with regard to the onset and progression of some
manifestations. In this sense, Fabry disease would resemble more
closely Krabbe disease in which the toxicmetabolite galactosylphin-
gosine (psychosine) rather than galactosylceramide is considered to
be a crucial factor in the pathogenesis (23). In this respect, it will be
valuable to establish the identity of lipid X (presumably also a
lyso-glycolipid) that also is present in Fabry plasma.
The role of lyso-Gb3 in the onset of various clinical signs of Fabry
disease should be firmly established. Provided that it is unequivo-
cally demonstrated that lyso-Gb3 contributes to disease manifes-
tations, measurement of its concentration in plasma may become a
valuable guide for clinical management. Monitoring of lyso-Gb3
possibly could assist in decision-making when therapeutic interven-
tion has to be initiated and which treatment regimen results in
individual patients in optimal prevention and/or correction. Our
investigation has indicated that ERT with recombinant -galacto-
sidases can reduce, but not easily normalize, plasma lyso-Gb3.
However, it is reassuring that the abnormality in lyso-Gb3 in Fabry
patients is at least partly responsive to ERT. The observed reduc-
tions in plasma lyso-Gb3 after ERT could be either caused by direct
intralysosomal degradation of lyso-Gb3 or result from intralysoso-
mal clearance of stored Gb3, limiting the source for production of
lyso-Gb3. In addition to existing ERTs, novel therapeutic avenues
that specifically target prevention of lyso-Gb3 formation or pro-
mote its removal also may become of interest in the future.
In summary, markedly elevated lyso-Gb3 constitutes a hallmark
of Fabry disease, and the potential role of this metabolite in the
manifestations of the disease warrants further investigation.
Materials and Methods
Fabry Patients, Plasma Specimens, and Cultured Fibroblasts. Selection from the
cohort of patients with Fabry disease at the Academic Medical Center in Amster-
dam was carried out for analysis of (glyco)sphingolipids and disease manifesta-
tions before the initiation of ERT. This selection included 17 classically affected
hemizygotes (age range 6–45 years), 17 heterozygotes (age range 11–52 years),
two newborns (1 hemizygote and 1 heterozygote), and 5 atypical hemizygotes
with the R112H mutation. In addition, 10 control subjects (five males and five
females) were included. A large Fabry family was part of this study, including an
affected mother and her affected sister, a healthy father, five hemizygous sons,
three heterozygous individuals, and five healthy siblings. Ten patients (eight
hemizygotes and two heterozygotes) received either 0.2 mg/kg agalsidase alfa
(Replagal, Shire) or 0.2 mg/kg or 1.0 mg/kg agalsidase beta (Fabrazyme, Gen-
zyme). The diagnosis of Fabry disease was confirmed by demonstration of defi-
cient activity of -galactosidase A in leukocytes and genotyping. Blood samples
were obtained with informed consent for investigations. Skin fibroblasts from
Fabry patients (n 2) and control individuals (n 2) were cultured as described
in ref. 41.
Clinical Assessments. A complete medical history was obtained, and physical
examination was performed on all patients. Clinical assessments are described in
detail in SI Text. Briefly, as described in ref. 7, renal function was analyzed and
brain magnetic resonance imaging, electrocardiograms, cardiac ultrasound in-
vestigations, hearing tests, and assessments of pain were carried out. Overall
severity of disease was assessed by using the MSSI (9).
Statistical Analysis. Correlations were calculated for hemizygotes and heterozy-
gotes separately, with the exclusion of the atypical cases carrying the R112H
mutation and the two newborns. Correlations between variables were described
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with the use of Spearman rank correlation coefficients. P values of 0.05 were
considered significant.
Fabry Mice. C3HeB/FeJ and B6;129-Glatm1Kul (stock number 003535) strains were
obtained from The Jackson Laboratory. Animals were fed a commercially avail-
able laboratory diet (RMH-B; Hope Farms, Woerden, The Netherlands).
Culture and Measurement of Proliferation of Smooth Muscle Cells. Smooth
musclecellswereobtainedfromCarliedeVries (Amsterdam).Smoothmusclecells
were seeded in 24-well plates at 1–4  104 cells per well and reached 60–70%
confluence after 24 h. Smooth muscle cells were made quiescent by incubation
for 24 h in FBS-free medium and then were stimulated for 24 h with 5% (vol/vol)
FBS. Subsequently, cells were labeled for 4 h with 0.25 Ci per well [methyl-
3H]thymidine (Amersham Biosciences). Incorporated [3H]thymidine was precipi-
tated for 30 min at 4°C with 10% (wt/vol) trichloroacetic acid, washed twice with
5%(wt/vol) trichloroaceticacid,anddissolvedin0.5MNaOH(0.5mlperwell),and
radioactivity was measured by liquid-scintillation counting.
Recombinant -Galactosidases. Agalsidase alfa (Replagal, Shire) and agalsidase
beta (Fabrazyme, Genzyme) were purchased from the local hospital pharmacy.
Enzyme Activity Assays. The enzymatic activity of -galactosidase A was deter-
mined with fluorogenic 4-methylumbelliferyl--galactoside as substrate (41).
Enzyme preparations were incubated at 37°C with 3.5 mM substrate in 100 mM
citrate/200 mM phosphate buffer (pH 4.6) at 37°C. Alternatively, enzymatic
activity was measured toward Gb3 in the presence of 0.5% (wt/vol) sodium
taurocholate in 50 mM sodium acetate buffer (pH 4.2). The formation lactosyl-
ceramide was determined by high-performance thin layer chromatography
(HPTLC) analysis (12).
Plasma Fractionation. Fasted EDTA plasma was obtained from a patient with
Fabry disease and an age- and gender-matched control subject. Lipoproteins
were separated by gradient ultracentrifugation according to the procedure of
Redgrave et al. (42).
Measurement of Neutral (Glyco)sphingolipids. Gb3, lactosylceramide, glucosyl-
ceramide, and ceramide were measured by using high-performance liquid chro-
matography as described in ref. 26. The mean Gb3 concentration in plasma from
controlswas1.7 (0.5)mol/liter (n40),meanconcentrationofglucosylceramide
in plasma from controls was 6.3 (1.9)mol/liter (n40), and mean concentration
of ceramide in plasma from controls was 9.0 (2.3) mol/liter (n 40) (26).
Measurement of lyso-Gb3 in Fabry Plasma and Tissues. To 100 l of plasma or
tissuehomogenates,50lofwaterwasadded,andthe lipidswereextractedwith
900 l of chloroform/methanol 1/2 (vol/vol). The extract was centrifuged for 10
min at 14,000g, and the supernatant was removed. To the supernatant, 0.3 ml
of chloroform and 0.45 ml of water were added, and after mixing, the phases
were separated by brief centrifugation. The upper phase was removed, and the
lower chloroform phase was extracted once more with 1.2 ml of methanol/water
1/1 (vol/vol). The combined upper phases were dried and taken up in 1 ml of
water, and the water phase was extracted twice with 1 ml of water-saturated
1-butanol. lyso-Gb3 was recovered from the butanol phase with an overall
recovery of 90%. The butanol phase was dried and dissolved in 120 l of
methanol. Of this solution, 50 l was taken to dryness, and the lyso-Gb3 was
derivatized with 25 l of o-phtaldialdehyde (OPA) reagent (5 mg of OPA, 0.1 ml
of ethanol, 5l of 2-mercaptoethanol, and 10 ml of 3% boric acid, pH 10.7). The
OPA-derivatized lyso-Gb3 was separated by HPLC and identified by fluorescence
detection as described in ref. 26. Quantification was by external standardization
after standard addition of authentic lyso-Gb3 (Sigma-Aldrich) to normal plasma
so that increasing concentrations from 0 to 1,000 nmol/liter plasma were ob-
tained. The response was strictly linear with the lyso-Gb3 concentration, and the
limit of quantification was 10 nmol/liter. Peak identification was by comparison
of the retention time with that of authentic lyso-Gb3.
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